İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris limited - atenololum inn - filmuhúðuð tafla - 25 mg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

dechra regulatory b.v. - phenobarbitalum inn - tafla - 100 mg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

dechra regulatory b.v. - phenobarbitalum inn - tafla - 25 mg

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - clidinii bromidum inn; chlordiazepoxidum inn - húðuð tafla

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - mesnum inn - stungulyf, lausn - 100 mg/ml

Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - crisantaspase - forvarnarfrumuæxli-eitilfrumuhvítblæði - Æxlishemjandi lyf - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.

Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

takeda pharmaceuticals international ag - icatibant - ofsabjúgur, arfgengur - hjarta meðferð - firazyr er ætlað til meðferðar við bráðri árás arfgengs ofsabjúgs (hae) hjá fullorðnum (með skort á c1-esterasa-hemlum).

Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

accord healthcare s.l.u. - icatibant acetate - ofsabjúgur, arfgengur - other hematological agents - icatibant accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 esterase inhibitor deficiency.

İzlanda - İzlandaca - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - icatibantum inn - stungulyf, lausn í áfylltri sprautu - 30 mg

Avrupa Birliği - İzlandaca - EMA (European Medicines Agency)

orion corporation - entacapone - parkinsonsveiki - anti-parkinsonslyf - skammti er ætlað sem viðbót til að standard undirbúning algengari / benserazide eða algengari / ddc hemli til að nota í fullorðinn sjúklinga með parkinsonsveiki og enda-af-skammt mótor sveiflur, sem ekki er hægt að stöðug á þeim sturtu.